Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

673.60 -0.67 (-0.10%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 623,019
Open 678.20
Bid (Size) 665.00 (1)
Ask (Size) 685.00 (1)
Prev. Close 674.27
Today's Range 671.55 - 684.00
52wk Range 642.00 - 1,211.20
Shares Outstanding 91,779,465
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years
Via Benzinga
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN
From The Rosen Law Firm PA
Via GlobeNewswire

Performance

YTD
-5.82%
-5.82%
1 Month
-2.83%
-2.83%
3 Month
-11.60%
-11.60%
6 Month
-43.72%
-43.72%
1 Year
-28.95%
-28.95%

More News

Read More
Discover the top S&P500 movers in Wednesday's pre-market session.
Via Chartmill
ROSEN, A LEADING LAW FIRM, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN
From The Rosen Law Firm PA
Via GlobeNewswire
Regeneron Announces Investor Conference Presentations
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
How Databricks Pounced On AI Opportunity Amid Snowflake, Palantir Rivalries
Via Investor's Business Daily
Topics Artificial Intelligence
Exposures Artificial Intelligence
Linvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Healthcare And Biotech Playbook As Disruption Gathers Force
Via Talk Markets
Topics ETFs Stocks / Equities
Eye Disease Focused 4D Molecular Therapeutics Lays Out 52-Week Results From Wet AMD Study
Via Benzinga
Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move
Via The Motley Fool
Earnings To Watch: Incyte (INCY) Reports Q4 Results Tomorrow
Via StockStory
EYLEA HD® (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Three-Year Results for EYLEA HD® (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Wall Street's Top 10 Stock Calls This Week - Saturday, Feb. 8
Via Talk Markets
Topics Stocks / Equities
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years
Via Benzinga
Regeneron Stock Down 30% Over Past 6 Months: Leerink Sees Buying Opportunity, Retail's On The Same Page
Via Stocktwits
Billions in Buybacks: 4 Stocks Rewarding Shareholders Now
Via MarketBeat
Arcutis Soared In 2024, Blazing Trails In Dermatology. Why Its CEO Eyes Bigger Gains.
Via Investor's Business Daily
Exposures Product Safety
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN
From The Rosen Law Firm PA
Via GlobeNewswire
Why Regeneron Pharmaceuticals Stock Topped the Market on Tuesday
Via The Motley Fool
Uncover the latest developments among S&P500 stocks in today's session.
Via Chartmill
Discover which S&P500 stocks are making waves on Tuesday.
Via Chartmill
Regeneron Pharma Q4 Earnings Crush Estimates, Initiates Dividend And Additional Stock Buyback Program
Via Benzinga
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals
From Faruqi & Faruqi LLP
Via GlobeNewswire
US Stocks Rise Despite China's Trade Fears, Palantir Defies Gravity, Gold Rallies Further: What's Driving Markets Tuesday?
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.